BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 32365386)

  • 21. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
    Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
    Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
    Li A; Garcia DA; Lyman GH; Carrier M
    Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
    Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis.
    Fuentes HE; McBane RD; Wysokinski WE; Tafur AJ; Loprinzi CL; Murad MH; Riaz IB
    Mayo Clin Proc; 2019 Dec; 94(12):2444-2454. PubMed ID: 31685262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
    Murphy AC; Koshy AN; Farouque O; Yeo B; Raman J; Kearney L; Yudi MB
    Heart Lung Circ; 2022 May; 31(5):716-725. PubMed ID: 34896013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials.
    Elbadawi A; Shnoda M; Mahmoud K; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):380-388. PubMed ID: 32556105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials.
    Haykal T; Zayed Y; Deliwala S; Kerbage J; Ponnapalli A; Malladi S; Goranta S; Samji V; Adam S
    Thromb Res; 2020 Oct; 194():57-65. PubMed ID: 32788122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of cancer-associated venous thromboembolism].
    Di Nisio M
    G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants.
    Carrier M; Soff G; Le Gal G
    Cancer Treat Res; 2019; 179():103-115. PubMed ID: 31317483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.
    Song AB; Rosovsky RP; Connors JM; Al-Samkari H
    Vasc Health Risk Manag; 2019; 15():175-186. PubMed ID: 31417269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.
    Vasanthamohan L; Boonyawat K; Chai-Adisaksopha C; Crowther M
    J Thromb Haemost; 2018 Jul; 16(7):1288-1295. PubMed ID: 29772108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
    Raskob G; Büller H; Prins M; Segers A; Shi M; Schwocho L; van Kranen R; Mercuri M;
    J Thromb Haemost; 2013 Jul; 11(7):1287-94. PubMed ID: 23574579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
    Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
    Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.